UCLA, Santa Monica, CA, USA.
LSU, New Orleans, LA, USA.
Curr Pain Headache Rep. 2021 Mar 24;25(5):30. doi: 10.1007/s11916-021-00947-2.
With the aging population, it is clear that the demand for future chronic pain treatment modalities is at an all-time high. One of the newest treatment modalities that is gaining popularity with both practitioners and patients alike is that of regenerative medicine and the use of stem cells to treat chronic painful conditions. This article aims to distill the most recent, available data from both laboratory research and clinical trials to better illuminate the potentials for these therapies in the treatment of chronic pain.
There are numerous investigations underway using mesenchymal stem cells (MSCs) to treat painful, largely degenerative conditions. A large majority of these investigations focus on osteoarthritis of the knee and have demonstrated significantly improved pain scores. Some of these investigations have demonstrated significantly increased articular cartilage and meniscus growth as well as improved function. These studies have been smaller (n, 18) and need to be corroborated on a macrolevel. Platelet-rich plasma (PRP)-based therapies have been most extensively studied in the treatment of knee osteoarthritis. Multiple prospective and randomized trials and meta-analyses have afforded level I evidence in support of PRP's safety and efficacy in chronic knee pain demonstrating both decreased pain (via VAS) and increased functional status (via WOMAC and IKDC). There have been randomized controlled trials examining PRP therapies in treatment degenerative disc disease (intradiscal treatment), facet arthropathy (intra-facet injections), and sacroiliitis (SIJ) which have all yielded similar positive results. Each RTC demonstrated decreased pain scores and increased function but lacks the scale to derive concrete guidelines. Newer investigations are underway examining modified PRP formulas with increased fibrin (PRF) or various growth factors (PRGF) and have shown positive outcomes with respect to osteoarthritic conditions in small trials. Animal trials are underway further investigating these therapies as well as specific gene modulation therapies. This review of the most recent investigations into the application and uses of biologic stem cell-derived treatments for chronic painful conditions should act to illustrate the growing, favorable data for these types of modalities both with respect to pain control and functional improvement.
随着人口老龄化,未来治疗慢性疼痛的需求达到了前所未有的高度。一种新的治疗方法,即再生医学和使用干细胞来治疗慢性疼痛疾病,正受到医生和患者的欢迎。本文旨在从实验室研究和临床试验中提取最新、最可用的数据,以更好地阐明这些疗法在治疗慢性疼痛方面的潜力。
目前有许多使用间充质干细胞(MSCs)治疗疼痛、主要是退行性疾病的研究正在进行中。绝大多数这些研究都集中在膝关节骨关节炎上,并已证明疼痛评分显著改善。其中一些研究还证明了关节软骨和半月板的生长以及功能的显著改善。这些研究规模较小(n=18),需要在宏观层面上加以证实。富含血小板的血浆(PRP)治疗在膝关节骨关节炎的治疗中得到了最广泛的研究。多项前瞻性和随机临床试验和荟萃分析提供了 I 级证据,支持 PRP 在慢性膝关节疼痛中的安全性和疗效,表明疼痛(通过 VAS)和功能状态(通过 WOMAC 和 IKDC)均降低。已经有随机对照试验研究了 PRP 治疗退行性椎间盘疾病(椎间盘内治疗)、小关节病(小关节内注射)和骶髂关节炎(SIJ),结果均为阳性。每个 RCT 均表明疼痛评分降低,功能改善,但缺乏制定具体指南的规模。正在进行新的研究,研究改良的 PRP 配方,增加纤维蛋白(PRF)或各种生长因子(PRGF),并在小试验中显示出对骨关节炎的积极结果。动物试验也在进一步研究这些治疗方法以及特定的基因调节治疗方法。对生物源性干细胞衍生治疗慢性疼痛疾病的最新研究的综述,应能说明这些治疗方法在控制疼痛和改善功能方面的有利数据不断增加。